Breast Pathway Group – EC (Epirubicin/Cyclophosphamide) in Advanced Breast Cancer

**Indication:** First line for advanced breast cancer with no prior exposure to anthracyclines

**Regimen details:**
- Epirubicin *60-90mg/m²* IV Day 1
- Cyclophosphamide 600mg/m² IV Day 1

* Consider Epirubicin 60mg/m² if patient > 60 years

**Administration:**
- Epirubicin IV bolus injection via a fast-running Sodium Chloride 0.9% infusion
- Cyclophosphamide may be administered as IV bolus injection via a fast-running Sodium Chloride 0.9% infusion or as a short infusion e.g. in 100-250ml Sodium Chloride 0.9% over 30 minutes

**Frequency:** Day 1, every 21 days, for 6 cycles

**Premedication:** Not routinely required

**Anti-emetics:** Highly emetogenic
- Follow local anti-emetic policy

**Supportive medication:** Mouthcare as per local policy

**Extravasation:**
- Epirubicin: vesicant
- Cyclophosphamide: Non-vesicant

Epirubicin should be administered with appropriate precautions to prevent extravasation. If there is any possibility that extravasation has occurred, contact a senior member of the medical team and follow local protocol for dealing with cytotoxic extravasation to reduce the risk of permanent tissue damage.
Breast Pathway Group – EC (Epirubicin/Cyclophosphamide) in Advanced Breast Cancer

Regular investigations:

Prior to Cycle 1:
- FBC Day 1 (within 14 days)
- LFTs Day 1 (within 14 days)
- U&Es Day 1 (within 14 days)
- MUGA scan/Echocardiogram See Comments

Prior to Day 1 (all cycles):
- FBC Day 1 (within 72 hours)
- LFTs Day 1 (within 72 hours)
- U&Es Day 1 (within 72 hours)

Toxicities:
- Myelosuppression, cardiotoxicity, mucositis, stomatitis, nausea, vomiting, diarrhoea, alopecia, urine discolouration, potential risk of infertility / early menopause, fatigue, skin sensitivity to sun exposure

DOSE MODIFICATIONS

Haematological Toxicity

<table>
<thead>
<tr>
<th>Neutrophils (x 10⁹/L)</th>
<th>Platelets (x 10⁹/L)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 1.5 &amp; ≥ 100</td>
<td></td>
<td>100% dose</td>
</tr>
<tr>
<td>&lt; 1.5 or &lt; 100</td>
<td></td>
<td>Delay for 1 week. Repeat FBC, if recovered resume at 100% dose. Consider dose reduction for &gt;1 delay.</td>
</tr>
</tbody>
</table>

- Dose reduction and / or delay is more appropriate in the advanced setting
- If during the preceding cycle, the patient has experienced neutrophils <0.5 x 10⁹/L or has febrile neutropenia diagnosed, GCSF should be considered
- If platelets persistently < 100 x 10⁹/L on Day 1 despite dose delay – see Consultant advice and consider dose reduction by 25%

Non-haematological Toxicities

Renal Impairment

Epirubicin

Consider dose reduction in severe renal impairment (GFR <10ml/min) or serum creatinine >3.0 – 6.0 x ULN. Discuss with the Consultant and consider dose reduction.

<table>
<thead>
<tr>
<th>Creatinine Clearance (ml/ml)</th>
<th>Cyclophosphamide Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 20</td>
<td>100% dose</td>
</tr>
<tr>
<td>10 - 20</td>
<td>75% dose</td>
</tr>
<tr>
<td>&lt; 10</td>
<td>50% dose</td>
</tr>
</tbody>
</table>

Disclaimer: The Joint Delivery Chemotherapy Nurse/Oncology Pharmacist Group is a sub-group of the Medicines & Chemotherapy Steering Group (MCSG) working within the London Cancer Alliance Integrated Cancer System (LCA). The output of the LCA MCSG includes documentation that can be adopted by healthcare organisations at their discretion. It is the responsibility of each individual organisation to ensure that appropriate governance and safety clearance procedures within their own clinical service have been followed prior to implementation of any such pieces of work. LCA assume no responsibility for this process within individual organisations, and no responsibility for the clinical management of individual patients or patient groups. Any clinical queries regarding individual patients or documentation should be directed to the relevant clinical team within the most appropriate healthcare organisation.

©LCA Copyright 2014
**Hepatic Impairment**

<table>
<thead>
<tr>
<th>Bilirubin (µmol/L)</th>
<th>Epirubicin Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>24-51</td>
<td>Give 50%</td>
</tr>
<tr>
<td>51-85</td>
<td>Give 25%</td>
</tr>
<tr>
<td>&gt;85</td>
<td>Omit</td>
</tr>
</tbody>
</table>

**Cyclophosphamide** is not recommended in patients with bilirubin >17 µmol/L or AST/ALT more than 2-3ULN, however, exposure to active metabolites may not be increased, therefore a dose reduction may not be necessary. Decision should be discussed with the Consultant.

**Dose modifications for other toxicities**

**Epirubicin**  
Mucositis may appear 5-10 days after the start of treatment, and usually involves stomatitis with areas of painful erosions, mainly along the side of the tongue and the sublingual mucosa. For grade III painful erythema or ulcers requiring IV rehydration resolving to Grade I or less painless ulcers or mild soreness: give Epirubicin 85% dose and recommend regular mouth care.

**Location of regimen delivery:**  
Outpatient setting

**Comments:**

**Epirubicin**  
Maximum cumulative dose epirubicin = 950mg/m²  
A baseline MUGA scan should be performed where the patient is considered at risk of having impaired cardiac function e.g. significant cardiac history, hypertension, obese, smoker, elderly, previous exposure to anthracyclines, previous thoracic radiotherapy.  
MUGA scan should be repeated if there is suspicion of cardiac toxicity at any point during treatment, or if cumulative anthracycline dose approaches maximum.

**Cyclophosphamide**  
Haematuria and haemorrhagic cystitis may rarely occur with cyclophosphamide administration (especially at doses above 1000mg). Patients should be monitored during therapy and encouraged to maintain adequate fluid intake whilst on therapy.

Pulmonary Fibrosis and Interstitial Pneumonitis is a rare complication of cyclophosphamide therapy and patients should be monitored for signs and symptoms of pulmonary dysfunction during treatment. Cyclophosphamide should be discontinued if fibrosis develops.
Drug interactions:

**Epirubicin**
Use of Epirubicin with cardioactive compounds (e.g. calcium channel blockers) requires careful monitoring throughout treatment. Avoid commencing epirubicin based therapy for up to 25 weeks after stopping trastuzumab therapy. Cimetidine and Ciclosporin: can increase Epirubicin serum level Verapamil: possibly increases Epirubicin bone marrow depressant effects

**Epirubicin and Cyclophosphamide**
Clozapine: increased risk of agranulocytosis, avoid concomitant use Digoxin tablets: reduced absorption (resolved by giving the digoxin in liquid) Phenytoin: reduced absorption of the antiepileptic

**Cyclophosphamide**
Allopurinol: can increase the incidence of serious bone marrow depression Amiodarone: increased risk of pulmonary fibrosis; avoid combination if possible Grapefruit juice: decreased or delayed activation of cyclophosphamide. Avoid grapefruit juice for 48 hours before and on day of cyclophosphamide Indapamide: prolonged leucopenia is possible Itraconazole: might increase Cyclophosphamide side effects e.g. haemorrhagic cystitis, pigmentation of palms, nails and soles etc. Warfarin: anticoagulant effect is increased

References:
UCLH- Dosage Adjustment for Cytotoxics in Renal Impairment. Jan 2009
UCLH- Dosage Adjustment for Cytotoxics in Hepatic Impairment. Jan 2009
LCA Breast Cancer Clinical Guidelines October 2013